ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

ClinicalTrials.gov ID: NCT02450552

Public ClinicalTrials.gov record NCT02450552. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 9:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis

Study identification

NCT ID
NCT02450552
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Brian Wainger
Other
Enrollment
65 participants

Conditions and interventions

Interventions

  • Ezogabine Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2015
Primary completion
Dec 31, 2017
Completion
Jan 31, 2018
Last update posted
Aug 27, 2019

2015 – 2018

United States locations

U.S. sites
12
U.S. states
10
U.S. cities
11
Facility City State ZIP Site status
Barrow Neuological Institute Phoenix Arizona 85013
Cedars-Sinai Los Angeles California 90048
UC Irvine Medical Center Orange California 92868
Mayo Clinic in Florida Jacksonville Florida 32224
Augusta University (Georgia Regents Medical Center) Augusta Georgia 30901
Johns Hopkins Hospital Baltimore Maryland 21287
Massachusetts General Hospital Boston Massachusetts 02114
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
University of Michigan Ann Arbor Michigan 48109
Hospital for Special Surgery New York New York 10021
Duke University Hospital Durham North Carolina 27705
Penn State College of Medicine Milton S. Hershey Medical Center Hershey Pennsylvania 17033

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02450552, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 27, 2019 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02450552 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →